Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prometheus launches AstraZeneca bowel capsules
AstraZeneca launched Entocort EC (budesonide) capsules in November 2001. In November 2004, Prometheus entered into an agreement with AstraZeneca for the marketing, sales and distribution of Entocort EC,
AstraZeneca launched Entocort EC (budesonide) capsules in November 2001. In November 2004, Prometheus entered into an agreement with AstraZeneca for the marketing, sales and distribution of Entocort EC,
The phase I/IIa, open-label, dose-escalation clinical trial is being conducted at three leading oncology centers in the US. It will include approximately 30 patients with colon, stomach or
The two antibodies, IMC-11F8 and IMC-1121B, both of which target growth factor receptors, are being evaluated for their potential as cancer therapeutics. Each antibody was isolated by ImClone
When obese diabetic animals (Zucker diabetic fatty rats) were fed large amounts of glucose, the amount of glucose in their blood increased to a higher level, and was
The escalating dose clinical study will evaluate both the safety profile and effects on painful symptoms and analgesic use. In addition, preliminary information regarding the effect of Quadramet
Following a 30-day waiting period after the submission of the investigational new drug (IND) application, ProEthic will begin clinical trials on patients with sports-related, soft-tissue injuries, such as
The new Together Rx Access Card offers savings on a broad range of pharmaceuticals through a free, easy-to-use card. The card will help uninsured Americans who meet income
Results from the phase I trial have been published in the journal, Vaccine. The authors conclude that Vaxin’s novel flu vaccine, which is produced in cell culture, was
The collaboration will combine Targeted Genetics’ adeno-associated virus (AAV) delivery platform with Sirna’s Huntington’s disease (HD) program and knowledge of RNA silencing technologies. The focus of the collaboration
The final analysis of the primary endpoint, time to disease progression, in the D9902A study, did not show a statistically significant delay in time to disease progression in